Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Thomas Filleron"'
Autor:
Damien Pouessel, Fanny Mathevet, Nadine Houede, Jean-Pierre Delord, Thomas Filleron, Raphaël Porcher, Jean-Yves Dauxois, Christine Chevreau, Stéphane Culine
Publikováno v:
Journal of Clinical Oncology. 39:e16512-e16512
e16512 Background: Immune-checkpoint-inhibitors (ICI) provide durable antitumor activity even for recurrent and/or metastatic disease. As illustrated in the Keynote-045 study (pembrolizumab (pembro.) in second line metastatic urothelial carcinoma; Fr
Autor:
Muriel Mounier, Paul Sargos, Laurent Votron, Damien Pouessel, Gilles Créhange, Mathieu Roumiguié, Thomas Filleron, Yohann Loriot, Naji Salem, Leonor Chaltiel, Pierre Graff-Cailleaud, Ulrike Schick, Christophe Hennequin, Pierre Blanchard, Jonathan Khalifa, Valentine Guimas, E. Meyer, Genevieve Loos, Angélique Massoubre, Nathalie Mesgouez-Nebout
Publikováno v:
Journal of Clinical Oncology. 39:TPS4588-TPS4588
TPS4588 Background: Consolidative local treatment of the primary tumor in the treatment of metastatic malignancies has shown promising results in several types of tumors, mostly relying on the seed-and-soil theory. Furthermore, the local treatment of
Autor:
Xavier Quantin, Pascale Dubray-Longeras, Nicolas Girard, Eric Dansin, Eric Pichon, Gaëtane Simon, Anne-Laure Martin, David Planchard, Didier Debieuvre, Sandrine Hiret, Christos Chouaid, Josiane Otto, Thomas Filleron, Radj Gervais, Roland Schott, Christelle Clément-Duchêne, Anne Madroszyk, Coureche Kaderbhai, Sophie Cousin, Maurice Pérol
Publikováno v:
Journal of Clinical Oncology. 39:9062-9062
9062 Background: In Europe, 10-15% of non-squamous non-small cell lung cancer (nsqNSCLC) have EGFR mutations of which 5-12% are an Exon 20 insertion (20ins). Methods: Analysis of Epidemio-Strategy and Medical Economics (ESME) Advanced and Metastatic
Autor:
Olivier Tredan, Olivia Le Saux, Jean-Sebastien Frenel, Jean-Yves Pierga, Thomas Bachelot, Charles Ferté, Thomas Filleron, Marta Jimenez, Laurence Albiges, Fabrice Andre, Antoine Italiano, F. Legrand, Céleste Lebbé, Valérie Boige, Fabrice Barlesi, Dominique Spaeth, Pierre-Etienne Heudel, Anthony Gonçalves, Laurent Mortier
Publikováno v:
Journal of Clinical Oncology. 37:TPS3159-TPS3159
TPS3159 Background: Molecular targeted agents (MTA) resulted in breakthroughs in selected niches. It is often assumed that tumor regression is consecutive to an oncogenic de-addiction effect. An emerging hypothesis suggests that genomic instability m
Autor:
Pierre Graff-Cailleaud, Jean-Marc Bachaud, Bernard Malavaud, Jonathan Khalifa, Richard Aziza, Amellie Lusque, Daniel Portalez, Thomas Brun, Thomas Filleron
Publikováno v:
Journal of Clinical Oncology. 35:124-124
124 Background: Biology suggests that the most significant focus drives the natural history of prostate cancer. We assessed the feasibility of ultrafocal brachytherapy (BT) of the index tumor. Methods: In a 2-step Simon’s design (&=0.1, ß=0.1), 17
Autor:
Etienne Chatelut, Marine Gross-Goupil, Aude Flechon, Pascale Olivier, Remy Delva, Loic Mourey, Stéphane Culine, Jean-Pierre Lotz, Fabienne Thomas, Christine Chevreau, Thomas Filleron, Christophe Massard, Gwenaelle Gravis, Karim Fizazi, Jacques-Olivier Bay
Publikováno v:
Journal of Clinical Oncology. 35:401-401
401 Background: HDCT is a valid option of treatment for relapsed advanced GCTs pts. The results of the TICE regimen as salvage therapy in poor risk pts demonstrated a 50% complete response (CR) but with very high variability of measured carboplatin a
Autor:
Alexander Drilon, Michel M. van den Heuvel, D. Ross Camidge, Julien Mazieres, Jin-Yuan Shih, Mark G. Kris, Benjamin Besse, Mark M. Awad, David P. Carbone, Oliver Gautschi, Nir Peled, Julie Milia, Juergen Wolf, Rafael Rosell, Florian Cabillic, Thomas Filleron, Dwight H. Owen, Pasi A. Jänne, Byoung Chul Cho, Daniel D. Karp
Publikováno v:
Journal of Clinical Oncology. 34:9014-9014
9014Background: Alongside prospective clinical trials for patients (pts) with non-small cell lung cancers (NSCLC) driven by rare genomic alterations, registries can provide complementary informatio...
Autor:
Delphine Bonnet, Bastien Cabarrou, Janick Selves, Christine Toulas, Thomas Filleron, Marie Danjoux, Rosine Guimbaud, Camille Herve, Anne Staub, Edith Chipoulet, Anne-Pascale Laurenty
Publikováno v:
Journal of Clinical Oncology. 33:e14629-e14629
e14629 Background: Lynch syndrome (LS) is the most frequent inherited colorectal cancer (CRC) syndrome, due to germline mutations in one of the mismatch repair (MMR) genes. Out of the 15% of CRCs associated with deficient DNA mismatch repair system (
Autor:
Laurence Gladieff, Carlos Gomez-Roca, Henri Roché, Jean-Pierre Delord, Eleonora De Maio, Florence Dalenc, Jean-Louis Lacaze, Thomas Filleron
Publikováno v:
Journal of Clinical Oncology. 33:e12028-e12028
e12028 Background: Eribulin is approved for the treatment of patients (pts) with advanced or metastatic breast cancer, after at least two regimens including an anthracycline and a taxane. Influence...
Autor:
Emmanuel Sevin, Laurent Balardy, L. Digue, Alain Ravaud, Thomas Filleron, Loic Mourey, Catherine Terret
Publikováno v:
Journal of Clinical Oncology. 33:TPS9635-TPS9635
TPS9635 Background: Efficacy and toxicity of targeted therapies don’t seem to vary considerably with age, but the impact of side effects in elderly patients is a major concern for clinicians. Our s...